WST
Research Snapshot
Static fundamentals, valuation context, and investor signals for WEST PHARMACEUTICAL SERVICES, INC. (WST).
HEALTHCARE
MEDICAL INSTRUMENTS & SUPPLIES
DCF ready
Valuation
N/A
EV/FCF, N/A FCF yield
Quality
14.6%
ROIC, 15.3% FCF margin
Growth
7.4%
5Y sales (revenue) CAGR
Balance sheet
0.1x
Debt/equity, 3.0x current ratio
Superinvestors
3
Top: Hillman Value Fund (1.6%)
Strengths to research
- Free cash flow compounded at 9.5% over five years.
- Free cash flow margin is healthy at 15.3%.
- Debt/equity looks manageable at 0.1x.
- 3 tracked superinvestors report a position.
Watchouts
- Valuation multiples are limited or unavailable.
Annual data: 10 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for WST.
Grade C
54
/ 100
Financial Charts
No financial data available for WST (annual).
3 superinvestors own WST
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| Bill & Melinda Gates Foundation Trust Bill & Melinda Gates Foundation Trust | 444,500 | $111M | 0.35% | 0.0% |
| Viking Global Investors Viking Global Investors | 416,948 | $105M | 0.29% | 0.0% |
| Hillman Value Fund Hillman Value Fund | 8,906 | $2M | 1.55% | 0.0% |